Parkinson's disease is a progressive neurodegenerative disorder that is characterized by the loss of dopamine neurons in the substanfia nigra pars compacta, resulfing in severe motor symptoms, which include a tremor at rest, rigidity, bradykinesia, akinesia and postural instability. In addition to motor deficits, there are a variety of non-motor symptoms associated with Parkinson's disease, including olfactory deficits, problems with gastrointesfinal mofility, sleep disturbances, sympathefic denervafion, anxiety, and depression. One of the promising areas of Parkinson's disease therapeufics is the administrafion of growth factors, such as glial cell derived neurotrophic factor (GDNF) or brain-derived neurotrophic factor (BDNF). Unfortunately, trials with GDNF and BDNF have not been successful, which is due, in part, to drug delivery and pharmacokinefic limitations. In collaboration with the Ye laboratory at Emory University, we have identified a class of orally active TrkB agonists that appear to recapitulate many of the actions of BDNF. Here we propose to test these novel compounds for their ability to restore funcfion in several animal models of Parkinson's disease. Based on preliminary evidence, we hypothesize that our novel orally-active TrkB agonists will restore function in these animal models. To test this hypothesis we propose to determine the ability of the novel TrkB agonists to restore funcfion in the MPTP mouse model (aim 1), to determine the anfiparkinsonian efficacy of the TrkB agonists in a chronic and progressive animal model of the disease that displays motor and non-motor deficits (VMAT2 LO mice, aim 2), and to determine the ability of these compounds to activate TrkB and alleviate symptoms in a non-human primate model of PD. Complefion of these specific aims will help us to determine the potential utility of selecfive and orally-acfive TrkB agonists as a therapeufic intervenfion for Parkinson's disease and posifion us to apply for further support from the NINDS Translafional Research Program.

Public Health Relevance

Parkinson's disease afflicts over one million U.S. citizens. Current dopaminergic treatments have limited efficacy, and often problematic side effects. This project is designed to test a new potential therapeutic intervenfion for the treatment of Parkinson's disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
5P50NS071669-05
Application #
8728333
Study Section
Special Emphasis Panel (ZNS1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
5
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Emory University
Department
Type
DUNS #
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Chen, Erdong; Paré, Jean-Francois; Wichmann, Thomas et al. (2016) Sub-synaptic localization of Cav3.1 T-type calcium channels in the thalamus of normal and parkinsonian monkeys. Brain Struct Funct :
Wichmann, Thomas; DeLong, Mahlon R (2016) Deep Brain Stimulation for Movement Disorders of Basal Ganglia Origin: Restoring Function or Functionality? Neurotherapeutics 13:264-83
Yung, Cheryl; Sha, Di; Li, Lian et al. (2016) Parkin Protects Against Misfolded SOD1 Toxicity by Promoting Its Aggresome Formation and Autophagic Clearance. Mol Neurobiol 53:6270-6287
Alter, Shawn P; Stout, Kristen A; Lohr, Kelly M et al. (2016) Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration. Exp Neurol 275 Pt 1:17-24
Bowman, F DuBois; Drake, Daniel F; Huddleston, Daniel E (2016) Multimodal Imaging Signatures of Parkinson's Disease. Front Neurosci 10:131
Galvan, Adriana; Hu, Xing; Smith, Yoland et al. (2016) Effects of Optogenetic Activation of Corticothalamic Terminals in the Motor Thalamus of Awake Monkeys. J Neurosci 36:3519-30
Sampat, Radhika; Young, Sarah; Rosen, Ami et al. (2016) Potential mechanisms for low uric acid in Parkinson disease. J Neural Transm (Vienna) 123:365-70
Sanders, Teresa H; Jaeger, Dieter (2016) Optogenetic stimulation of cortico-subthalamic projections is sufficient to ameliorate bradykinesia in 6-ohda lesioned mice. Neurobiol Dis 95:225-37
Devergnas, Annaelle; Chen, Erdong; Ma, Yuxian et al. (2016) Anatomical localization of Cav3.1 calcium channels and electrophysiological effects of T-type calcium channel blockade in the motor thalamus of MPTP-treated monkeys. J Neurophysiol 115:470-85
Iskhakova, Liliya; Smith, Yoland (2016) mGluR4-containing corticostriatal terminals: synaptic interactions with direct and indirect pathway neurons in mice. Brain Struct Funct 221:4589-4599

Showing the most recent 10 out of 83 publications